Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2019 06:00 ET | Source: Quotient Limited

Quotient Limited Provides Positive Updates on MosaiQ’s Initial Serological Disease Screening and Expanded Immunohematology Microarrays, on Hypercare Launch and on a Successful Facility Audit and Reports Second Quarter Fiscal 2020 Financial Results

Positive results from the initial Serological Disease Screening microarray US field trialPositive Verification and Validation data for expanded Immunohematology microarrayAn additional three Hypercare...
October 31, 2019 08:00 ET | Source: Quotient Limited

Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial

JERSEY, Channel Islands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the...
October 21, 2019 06:00 ET | Source: Quotient Limited

Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call

JERSEY, Channel Islands, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second...
October 17, 2019 16:51 ET | Source: Quotient Limited

Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter

Successful Extended Immunohematology Verification and Validation data paving the way for field trialsPositive customer feedback and three additional hypercare sites initiatedPreliminary quarterly...
August 05, 2019 06:15 ET | Source: Quotient Limited

Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results

First European hypercare launch site initiated following CE mark approvalInitial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological...
July 22, 2019 08:00 ET | Source: Quotient Limited

Quotient Limited to Report First Quarter 2020 Financial Results and Host Conference Call

JERSEY, Channel Islands, July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter...
July 02, 2019 08:00 ET | Source: Quotient Limited

Quotient Board Announces Contract Extension of CEO Franz Walt

JERSEY, Channel Islands, July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced...
July 01, 2019 07:00 ET | Source: Quotient Limited

Quotient Limited Announces the Submission of the Initial SDS Microarray CE mark Filing for MosaiQ™

JERSEY, Channel Islands, July 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced...
June 05, 2019 08:00 ET | Source: Quotient Limited

Quotient Limited to Participate in the Raymond James Life Sciences and MedTech Conference

JERSEY, Channel Islands, June 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris...
May 28, 2019 06:00 ET | Source: Quotient Limited

Quotient Limited Recaps Recent Milestone Achievement and Updates on the Initial Serological Disease Screening CE Mark Submission, planned 2019 US Field Trials and Reports Record Financial Results

CE mark received on the initial Immunohematology microarray in April 20192018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to permit commercialization...